BiotechTube

VAY736 + lenalidomide

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Conditions

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Trial Timeline

Jan 24, 2022 → Feb 24, 2025

NCT ID
NCT04903197

About VAY736 + lenalidomide

VAY736 + lenalidomide is a phase 1 stage product being developed by Novartis for Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04903197. Target conditions include Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma.

What happened to similar drugs?

8 of 20 similar drugs in Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma were approved

Approved (8) Terminated (1) Active (11)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved
✅ibritumomab tiuxetan (Zevalin®)BiogenApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04903197Phase 1Terminated

Competing Products

20 competing products in Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY4152199 - IVEli LillyPhase 1
36
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
PirtobrutinibEli LillyPhase 2
42
Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Eli LillyPhase 2
42
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8AbbViePhase 1/2
32
Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + LenalidomideAbbViePhase 1/2
36
Siltuximab + EpcoritamabAbbViePhase 1
36